Epidemiology, etiopathogenesis, and management of MRONJ: A European multicenter study

IF 1.8 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

Journal of Stomatology Oral and Maxillofacial Surgery Pub Date : 2024-09-01 DOI:10.1016/j.jormas.2024.101931

{"title":"Epidemiology, etiopathogenesis, and management of MRONJ: A European multicenter study","authors":"","doi":"10.1016/j.jormas.2024.101931","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>The purpose of this European multicenter study was to describe the general characteristics and risk factors of MRONJ<span><span> lesions as well as their clinical diagnosis and management at different European Oral and Maxillofacial Surgery centers, in order to minimize selections biases and provide information about the epidemiology, etiopathogenesis, and the current trends in the treatment of </span>MRONJ across Europe.</span></p></div><div><h3>Materials and methods</h3><p>The following data were registered for each patient: gender; age at MRONJ diagnosis; past medical history<span><span>; indication for antiresorptive or antiangiogenic therapy; type of antiresorptive medication; local risk factor for MRONJ; MRONJ Stage; anatomic location and symptoms; treatment; </span>surgical complications; recurrence.</span></p></div><div><h3>Results</h3><p><span>A total of 537 patients (375 females, 162 males) with MRONJ were included. Statistically significant associations were found between patients with metastatic bone disease and recurrences (</span><em>P</em> < 0.0005) and between advanced MRONJ stages (stages 2 and 3) and recurrences (<em>P</em> < 0.005). Statistically significant associations were also found between male gender and recurrences (<em>P</em> < 0.05), and between MRONJ maxillary sites and recurrences (<em>P</em> < 0.0000005).</p></div><div><h3>Conclusions</h3><p><span><span>A longer mean duration of antiresorptive medications before MRONJ onset was observed in patients affected by osteoporosis, whereas a shorter mean duration was observed in all metastatic bone cancer patients, and in particular in those affected by </span>prostate cancer<span> with bone metastases or </span></span>multiple myeloma. Surgery plays an important role for the management of MRONJ lesions.</p></div>","PeriodicalId":55993,"journal":{"name":"Journal of Stomatology Oral and Maxillofacial Surgery","volume":"125 5","pages":"Article 101931"},"PeriodicalIF":1.8000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Stomatology Oral and Maxillofacial Surgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468785524001770","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

The purpose of this European multicenter study was to describe the general characteristics and risk factors of MRONJ lesions as well as their clinical diagnosis and management at different European Oral and Maxillofacial Surgery centers, in order to minimize selections biases and provide information about the epidemiology, etiopathogenesis, and the current trends in the treatment of MRONJ across Europe.

Materials and methods

The following data were registered for each patient: gender; age at MRONJ diagnosis; past medical history; indication for antiresorptive or antiangiogenic therapy; type of antiresorptive medication; local risk factor for MRONJ; MRONJ Stage; anatomic location and symptoms; treatment; surgical complications; recurrence.

Results

A total of 537 patients (375 females, 162 males) with MRONJ were included. Statistically significant associations were found between patients with metastatic bone disease and recurrences (P < 0.0005) and between advanced MRONJ stages (stages 2 and 3) and recurrences (P < 0.005). Statistically significant associations were also found between male gender and recurrences (P < 0.05), and between MRONJ maxillary sites and recurrences (P < 0.0000005).

Conclusions

A longer mean duration of antiresorptive medications before MRONJ onset was observed in patients affected by osteoporosis, whereas a shorter mean duration was observed in all metastatic bone cancer patients, and in particular in those affected by prostate cancer with bone metastases or multiple myeloma. Surgery plays an important role for the management of MRONJ lesions.

查看原文本刊更多论文

MRONJ的流行病学、发病机制和治疗：一项欧洲多中心研究。

简介：这项欧洲多中心研究的目的是描述MRONJ病变的一般特征和风险因素，以及欧洲不同口腔颌面外科中心的临床诊断和管理，以尽量减少选择偏差，并提供有关欧洲MRONJ的流行病学、发病机制和当前治疗趋势的信息：对每位患者的以下数据进行登记：性别；MRONJ 诊断时的年龄；既往病史；抗骨吸收或抗血管生成治疗的指征；抗骨吸收药物的类型；MRONJ 的局部危险因素；MRONJ 分期；解剖位置和症状；治疗；手术并发症；复发：共纳入537例MRONJ患者（女性375例，男性162例）。结果：共纳入537名MRONJ患者（女性375人，男性162人），发现转移性骨病患者与复发（P＜0.0005）、MRONJ晚期（2期和3期）与复发（P＜0.005）之间存在统计学意义上的显著关联。男性性别与复发之间（P < 0.05）、MRONJ上颌骨部位与复发之间（P < 0.0000005）也存在统计学意义：结论：骨质疏松症患者在MRONJ发病前服用抗骨质吸收药物的平均时间较长，而所有转移性骨癌患者，尤其是前列腺癌骨转移患者或多发性骨髓瘤患者服用抗骨质吸收药物的平均时间较短。手术在治疗 MRONJ 病变方面发挥着重要作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊